Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 25 opinions in the last 12 months.
Johnson & Johnson has faced challenges due to ongoing talcum powder litigation and a recent significant acquisition that has impacted its credit rating. Despite these headwinds, experts believe the company has a strong foundation with stable earnings, cash flow, and an attractive dividend yield of around 3-3.5%. Many analysts express confidence in JNJ's ability to navigate through its current difficulties as well as its potential for future growth, particularly in the pharmaceutical and medical device sectors. However, they note that the company's current valuation means it hasn't been this cheap in many years, and some view it as a good opportunity for long-term investors. Overall, while concerns remain regarding its growth and litigation issues, many experts recommend holding or gradually accumulating shares, anticipating that the stock's value may increase once legal uncertainties are resolved.
It is in the medical devices and pharma spaces and has spun off the consumer care division. The overhang is the talcum powder litigation. He hopes it will be settled before too long and then investors can concentrate on the growth aspect of the stock. It has set aside 8 to 10 billion dollars for a settlement.
Stock performance somewhat disappointing. She'd keep holding. After KVUE spinoff now simply a medical device, medical tech, and pharma company. Some drugs are going off patent, but successful in developing pipeline. Company still expects revenue to grow slightly as time goes on.
Very strong balance sheet, AAA credit rating. Nice dividend, increases every year. Ongoing talc litigation is the overhang, but positive steps toward resolution. Then PE multiple should lift.
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
In the last year, 9 stock analysts published opinions about JNJ-N. 3 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.
Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
On 2025-04-07, Johnson & Johnson (JNJ-N) stock closed at a price of $150.62.
After spinoff, now just pharma and medical technologies/devices. One of 2 AAA-rated US companies (the other is MSFT). Pristine balance sheet forever. Divvy increases for 62 consecutive years, all from free cashflow. Crazy-cheap valuation of 14-15x PE, partly due to ongoing talc litigation. Yield is 3.34%.
(Analysts’ price target is $170.36)Recent press release was like none other. Company stated talc litigation based on fake science; if the other side won't settle, JNJ will litigate each and every case separately. He suspects this is a ploy to force a settlement. Expects it to be over by year's end.